A bill for an act relating to contract pharmacies and covered entities that participate in the 340B drug program. (Formerly HSB 137.) Effective date: 07/01/2023.
Impact
HF 423 changes existing state law by specifically addressing the treatment of covered entities and contract pharmacies within Iowa. The new provisions declare that these entities must receive equitable reimbursement compared to similarly situated ones not participating in the 340B drug program. Additionally, it empowers the commissioner of insurance to enforce compliance and penalize violations, which positions oversight for the 340B program firmly within the state regulatory framework. By highlighting violations as unfair or deceptive acts, the bill reinforces a commitment to maintaining fair practices in the healthcare market.
Summary
House File 423 aims to regulate the interactions between contract pharmacies and covered entities that participate in the 340B drug program. This legislation is intended to prevent discrimination against entities involved in the program by ensuring they are treated equitably regarding reimbursement for covered outpatient drugs. The bill states that group health plans, health carriers, and pharmacy benefits managers cannot impose unfavorable contractual terms or conditions exclusively on entities associated with the 340B program, which is designed to provide discounted medications to eligible patients. This legislative effort seeks to enhance access to affordable healthcare by safeguarding the financial integrity of participants in the 340B program.
Sentiment
The sentiment surrounding HF 423 has been generally positive, especially among advocates for healthcare affordability who see the bill as a critical step toward ensuring that vulnerable populations continue to have access to necessary medications at reduced costs. Supporters argue that by curbing discrimination against contract pharmacies and covered entities, the bill can help maintain the viability of the 340B program. However, there may be underlying concerns from some stakeholders about the potential consequences for private insurers and pharmacy benefits managers, who may oppose perceived additional regulations imposed by the state.
Contention
Notable points of contention include discussions surrounding the potential impact that HF 423 could have on the operational capabilities of insurance providers and pharmacy benefit managers. Some stakeholders worry that strict enforcement of the bill could lead to increased operational costs or complicated compliance measures that may ultimately affect consumers. While the goal of the bill is to protect disadvantaged groups from discriminatory practices, there are debates around the trade-offs regarding the broader implications for market dynamics within the healthcare sector.
Pharmacies; prohibit drug manufacturer and wholesalers from preventing a licensed pharmacy from acquiring drugs from entities that participate in a particular federal drug discount program
A bill for an act relating to pharmacy benefits managers, pharmacies, prescription drugs, and pharmacy services administrative organizations, and including applicability provisions. (Formerly SSB 1074.) Effective date: 07/01/2025. Applicability date: 07/01/2025.
Health: pharmaceuticals; drug manufacturers from engaging in certain conduct with pharmacies participating with a 340B program; prohibit. Amends 1978 PA 368 (MCL 333.1101 - 333.25211) by adding sec. 17757c. TIE BAR WITH: SB 95'25